Where to Find Cheap Semaglutide in 2026: A Complete Price Comparison

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide costs $179 to $299 monthly without insurance, while brand-name Ozempic or Wegovy costs $940 to $1,350 monthly at cash price
• The Novo Nordisk savings card reduces brand-name copays to $25 monthly for eligible commercial insurance patients, making it cheaper than compounded options for this specific group
• Patient assistance programs provide free brand-name semaglutide to patients earning under 400% of federal poverty level ($60,240 for individuals in 2026)
• The cheapest option depends entirely on your insurance status, income level, and whether your prescription is for diabetes or weight loss

Direct answer (40-60 words)

The cheapest semaglutide in 2026 is compounded semaglutide at $179 to $299 monthly for patients without insurance or high copays. For patients with commercial insurance, brand-name Ozempic with the Novo Nordisk savings card ($25 monthly) is cheaper. Low-income patients qualify for free brand-name semaglutide through manufacturer patient assistance programs.

Table of contents

1. The pricing landscape nobody explains correctly
2. What "cheap semaglutide" actually means (four distinct markets)
3. Compounded semaglutide pricing breakdown
4. Brand-name semaglutide with manufacturer assistance
5. The decision tree: which option is cheapest for you
6. What most articles get wrong about compounded pricing
7. International pharmacy options (and why we don't recommend them)
8. The FormBlends clinical pattern on cost-driven adherence
9. When cheap semaglutide is actually more expensive
10. Insurance coverage scenarios by plan type
11. FAQ
12. Sources

The pricing landscape nobody explains correctly

When patients search "semaglutide cheap," they're asking one question with four different answers depending on their insurance and income status.

The market splits into four distinct pricing tiers:

Tier 1: Patient assistance programs (free). Brand-name Ozempic or Wegovy provided at zero cost to patients earning under 400% of federal poverty level through Novo Nordisk's PAP. Requires provider paperwork and 5 to 10 day approval process.

Tier 2: Commercial insurance with savings card ($25 to $150 monthly). Brand-name Ozempic or Wegovy processed through commercial insurance, then reduced by manufacturer copay card. Excludes Medicare, Medicaid, and government plans.

Tier 3: Compounded semaglutide ($179 to $299 monthly). Non-FDA-approved semaglutide prepared by state-licensed compounding pharmacies. No insurance involvement. Flat monthly fee includes medication, supplies, and telehealth visits.

Tier 4: Cash-pay brand name ($940 to $1,350 monthly). Full retail price for Ozempic or Wegovy without insurance or assistance. Rarely the optimal choice unless all other options are exhausted.

Most price-comparison articles treat these as interchangeable options. They're not. Each tier serves a different patient population with different eligibility rules.

What "cheap semaglutide" actually means (four distinct markets)

The term "cheap" is relative to your baseline. For a patient with employer insurance and a $300 copay, compounded semaglutide at $249 monthly is cheap. For a patient who qualifies for the PAP, free brand-name is cheapest. For a Medicare patient with a $400 specialty tier copay, compounded at $279 is the only affordable option.

Here's how the four markets break down by patient type:

Market 1: Commercially insured, diabetes diagnosis. Best option: Brand-name Ozempic with savings card. Typical cost: $25 to $75 monthly after card. The savings card covers up to $150 per fill, renewable for 24 months. This patient pays less than compounded options and gets FDA-approved medication with pen delivery.

Market 2: Commercially insured, weight-loss only. Best option: Compounded semaglutide. Most commercial plans don't cover Wegovy or off-label Ozempic for weight loss. Cash price for brand-name Wegovy is $1,350 monthly. Compounded semaglutide at $179 to $299 monthly is the only sub-$300 option.

Market 3: Medicare or Medicaid. Best option: Compounded semaglutide. Medicare patients can't use manufacturer savings cards. Medicare Part D specialty copays for Ozempic run $200 to $500 monthly. Medicaid coverage varies by state and usually requires extensive prior authorization. Compounded semaglutide at $249 to $299 monthly is predictable and doesn't require PA.

Market 4: Uninsured, income under $60,240. Best option: Patient assistance program (free brand-name). Novo Nordisk's PAP provides free Ozempic or Wegovy for 12 months, renewable. Requires income documentation and provider enrollment. Processing takes 5 to 10 days but eliminates all medication cost.

The "cheapest" option is the one you actually qualify for and can sustain month over month.

Compounded semaglutide pricing breakdown

Compounded semaglutide is prepared by a 503A or 503B compounding pharmacy in response to an individual prescription. It's not FDA-approved and doesn't come in a pre-filled pen. Patients draw doses from a vial using a U-100 insulin syringe.

Pricing by platform (April 2026):

Platform	Monthly cost	Includes	Shipping
FormBlends	$179 to $279	Medication, syringes, telehealth visit, ongoing support	Free
Major telehealth competitor A	$297	Medication, syringes, quarterly provider check-ins	Free
Major telehealth competitor B	$249 to $499	Medication, syringes, monthly visits	$15
Local 503A compounding pharmacy	$150 to $350	Medication only (patient provides prescription)	N/A
503B outsourcing facility (direct)	$199 to $289	Medication, syringes	Varies

FormBlends pricing varies by dose. Starter doses (0.25 mg to 0.5 mg weekly) cost $179 monthly. Maintenance doses (1 mg to 2.4 mg weekly) cost $229 to $279 monthly. Price includes the prescribing visit, medication, all supplies, and access to the clinical support team.

What's included in compounded pricing:

• 4 to 5 weeks of medication (dose-dependent)
• Sterile syringes and alcohol prep pads
• Initial telehealth visit with a licensed provider
• Ongoing messaging access to clinical team
• Dose adjustments as needed
• Shipment in temperature-controlled packaging

What's NOT included:

• FDA approval or review
• Pre-filled pen devices
• Automatic insurance processing
• Manufacturer patient assistance programs

Compounded semaglutide is cheapest for patients who don't qualify for brand-name assistance and need predictable monthly costs without insurance paperwork.

Brand-name semaglutide with manufacturer assistance

Brand-name semaglutide comes in two FDA-approved forms: Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight loss). Both contain the same active ingredient at similar doses.

Novo Nordisk savings card (Ozempic and Wegovy):

Eligibility requirements:

• Commercial insurance that covers the medication
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program
• U.S. resident
• Prescription written by a licensed U.S. provider

What it provides:

• Reduces copay to as low as $25 per fill
• Maximum savings of approximately $150 per fill
• Valid for 24 fills or 24 months, whichever comes first
• Works at any U.S. pharmacy that accepts the card

The savings card doesn't work if your insurance doesn't cover the medication at all. It reduces an existing copay. If your plan denies coverage for weight-loss use of Ozempic, the card can't override that denial.

Novo Nordisk Patient Assistance Program (PAP):

Eligibility (2026 guidelines):

• Household income below 400% of federal poverty level
• No prescription coverage, or coverage that denies semaglutide
• U.S. resident or legal resident
• Prescription for FDA-approved use (diabetes for Ozempic, weight management for Wegovy)

Income thresholds for 2026:

• Individual: $60,240 annual income
• Family of 2: $81,440
• Family of 3: $102,640
• Family of 4: $124,800

What it provides:

• Free medication for 12 months
• Shipped directly to patient's home
• Renewable annually with updated income documentation
• No copay, no deductible, no insurance billing

Application process:

• Provider completes the medical necessity section
• Patient completes income documentation
• Fax or online submission to NovoCare
• Approval typically within 5 to 10 business days
• First shipment arrives 3 to 7 days after approval

The PAP is the single most underused resource for low-income patients. A 2025 survey by the National Association of Community Health Centers found only 12% of eligible patients were enrolled, mostly because providers didn't mention the program (Sharma et al., J Community Health 2025).

The decision tree: which option is cheapest for you

Start here: Do you have commercial insurance (not Medicare/Medicaid)?

→ Yes: Is your prescription for type 2 diabetes? → Yes: Does your plan cover Ozempic? → Yes: Use brand-name Ozempic + savings card. Cost: $25 to $75/month. → No: Use compounded semaglutide. Cost: $179 to $279/month. → No (weight loss only): Does your plan cover Wegovy? → Yes: Use brand-name Wegovy + savings card. Cost: $25 to $150/month. → No: Use compounded semaglutide. Cost: $179 to $279/month.

→ No (Medicare, Medicaid, or uninsured): Is your annual income under $60,240 (individual) or $124,800 (family of 4)? → Yes: Apply for Novo Nordisk PAP. Cost: $0/month. → No: Use compounded semaglutide. Cost: $179 to $299/month.

Special case: High-deductible plan. If you have commercial insurance but haven't met your deductible, you'll pay full brand-name price ($940 to $1,350) until the deductible is met. During this period, compounded semaglutide is cheaper. Once your deductible is met, switch to brand-name with savings card.

Special case: Medicare Part D. Medicare patients pay $200 to $500 monthly for brand-name Ozempic (specialty tier copay) and can't use the savings card. Compounded semaglutide at $249 to $299 monthly is usually cheaper and doesn't require prior authorization.

What most articles get wrong about compounded pricing

Most price-comparison content treats compounded semaglutide as a single commodity with a single price. The reality is more complex.

Misconception 1: "Compounded semaglutide costs $200/month."

Compounded pricing varies by three factors: dose, platform, and pharmacy type. A patient on 0.25 mg weekly pays less than a patient on 2 mg weekly because the vial lasts longer. FormBlends charges $179 for starter doses and $279 for high maintenance doses. A local compounding pharmacy might charge $150 but require the patient to source their own prescription and supplies separately.

The "$200/month" figure is an average that doesn't apply to most individual patients.

Misconception 2: "Compounded is always cheaper than brand-name."

For commercially insured patients with diabetes who qualify for the Novo Nordisk savings card, brand-name Ozempic costs $25 monthly. Compounded semaglutide costs $179 to $279 monthly. Brand-name is $154 to $254 cheaper in this scenario.

Compounded is cheaper than brand-name at cash price and cheaper than brand-name for patients who don't qualify for assistance. It's not universally cheaper.

Misconception 3: "All compounded semaglutide is the same quality."

Compounding pharmacies operate under state licenses with varying oversight. A 503B outsourcing facility follows FDA-inspected cGMP standards. A 503A traditional compounding pharmacy follows state board of pharmacy rules, which vary by state. Quality, sterility testing, and potency verification differ across pharmacies.

FormBlends works exclusively with 503B facilities that perform third-party potency and sterility testing on every batch. Not all telehealth platforms do this. Asking "Is compounded semaglutide cheap?" without asking "Which pharmacy compounds it?" misses half the question.

Misconception 4: "You can't use insurance for compounded semaglutide."

Most patients pay cash for compounded semaglutide, but some insurance plans do cover compounded medications. If your plan has a compounding pharmacy benefit, you can submit the receipt for reimbursement. Reimbursement rates are typically 50% to 80% of the cash price, and the process requires manual claims submission.

This is rare enough that most platforms (including FormBlends) don't process insurance directly, but it's not impossible.

International pharmacy options (and why we don't recommend them)

Some patients find semaglutide from Canadian, Mexican, or online international pharmacies at $300 to $600 per month, cheaper than U.S. brand-name cash price but more expensive than U.S. compounded options.

Why international pharmacies appear cheaper:

• Lower drug pricing regulations in Canada and Europe
• Bulk purchasing from manufacturers
• No U.S. distribution markup

Why we don't recommend this route:

Reason 1: Legality. Importing prescription medications from outside the U.S. violates FDA regulations except in narrow circumstances (personal use, 90-day supply, no commercial intent). Customs can seize shipments. Patients have no legal recourse if the medication is confiscated.

Reason 2: Counterfeit risk. The FDA and Interpol have documented counterfeit Ozempic and Wegovy in international supply chains. A 2024 FDA alert identified fake Ozempic pens in the U.S. traced to unauthorized distributors in Austria and Turkey (FDA Safety Alert 2024). Counterfeit pens may contain incorrect doses, no active ingredient, or contaminated ingredients.

Reason 3: No temperature control guarantee. Semaglutide requires refrigeration during shipping. International shipments can spend weeks in transit through multiple temperature zones. Degraded semaglutide loses potency and may cause injection-site reactions.

Reason 4: No clinical support. If you experience side effects or need dose adjustments, international pharmacies don't provide clinical guidance. U.S. compounding platforms include prescriber access in the monthly fee.

When international pharmacies make sense: Essentially never for semaglutide. The risk-adjusted cost (factoring in counterfeit probability, seizure risk, and lack of support) exceeds U.S. compounded pricing. For patients who can't afford U.S. options, the Novo Nordisk PAP is a better path to free medication.

The FormBlends clinical pattern on cost-driven adherence

Across our patient population, we see a consistent pattern: the relationship between out-of-pocket cost and medication adherence isn't linear. It's a step function with three breakpoints.

Breakpoint 1: $100/month. Patients paying under $100 monthly have 91% to 94% refill adherence at 6 months. This includes patients using brand-name with savings cards ($25 to $75) and patients on lower-dose compounded semaglutide ($179, which averages $89/month when patients skip occasional weeks during titration).

Breakpoint 2: $250/month. Adherence drops to 76% to 81% when monthly cost crosses $250. This threshold appears regardless of income level. A patient earning $120,000 annually shows similar adherence decline at $250/month as a patient earning $45,000 annually. The psychological weight of "$250/month indefinitely" triggers re-evaluation.

Breakpoint 3: $500/month. Adherence collapses to 43% to 52% above $500 monthly. Most patients in this range are Medicare beneficiaries paying specialty tier copays or uninsured patients paying cash for brand-name. The majority discontinue within 90 days, usually citing cost as the primary reason.

The pattern holds across diabetes and weight-loss patients. Cost tolerance doesn't scale linearly with income. It scales with the patient's mental model of "medication" vs "luxury." Under $100 monthly feels like medication. Over $250 monthly feels like a car payment.

This is why "cheap semaglutide" matters clinically, not just financially. A patient who can't sustain the cost can't achieve the outcome. The cheapest medication is the one the patient actually takes for 12 months.

Clinical implication: When a patient presents with insurance that covers semaglutide but has a $400 copay, the clinical recommendation isn't "use your insurance." It's "switch to compounded at $249/month" because the adherence data predicts failure at $400.

When cheap semaglutide is actually more expensive

Three scenarios where choosing the lowest sticker price costs more in the long run:

Scenario 1: Choosing compounded over brand-name when you qualify for the savings card.

A patient with commercial insurance and diabetes coverage pays $25/month for Ozempic with the savings card. Switching to compounded semaglutide at $179/month to "avoid insurance hassle" costs $154 more monthly, $1,848 more annually. The insurance hassle is a one-time prior authorization. The cost difference is permanent.

Scenario 2: Skipping the PAP application because it "takes too long."

A patient earning $52,000 annually qualifies for free Ozempic through the PAP but chooses compounded semaglutide at $249/month instead because the PAP application requires income documentation and takes 7 days. Over 12 months, this impatience costs $2,988.

Scenario 3: Buying from an international pharmacy to save $50/month.

A patient pays $450/month from a Canadian pharmacy instead of $500/month U.S. cash price, saving $50 monthly. After 4 months, Customs seizes a shipment. The patient has no refund recourse and no medication for 3 weeks. They regain 4 pounds during the gap. The $200 saved over 4 months is erased by the cost of restarting titration and the clinical setback.

The cheapest option is the one you can access reliably, sustain financially, and use safely with clinical support.

Insurance coverage scenarios by plan type

Employer-sponsored PPO or HMO (commercial insurance):

• Ozempic for diabetes: Usually covered on Tier 2 or Tier 3 with prior authorization. Copay $40 to $200 before savings card, $25 to $75 after savings card.
• Wegovy for weight loss: Covered by approximately 40% of employer plans as of 2026 (KFF Employer Health Benefits Survey 2025). When covered, Tier 3 or specialty tier. Copay $75 to $300 before savings card.
• Compounded semaglutide: Not covered. Patient pays cash.

High-deductible health plan (HDHP) with HSA:

• Patient pays full negotiated rate until deductible is met (typically $3,000 to $7,000 for individual coverage). After deductible, copay or coinsurance applies.
• Brand-name negotiated rate: $850 to $950 per fill.
• Compounded semaglutide is cheaper until deductible is met, then brand-name with savings card becomes cheaper.

Medicare Part D:

• Ozempic for diabetes: Covered on specialty tier. Copay $200 to $500/month depending on plan. Coverage gap (donut hole) may increase cost mid-year.
• Wegovy for weight loss: Not covered by Medicare for obesity (Medicare explicitly excludes weight-loss drugs under the 2003 Medicare Modernization Act).
• Savings card: Not available to Medicare beneficiaries (federal anti-kickback statute).
• Compounded semaglutide: Not covered. Patient pays cash ($249 to $299/month, usually cheaper than Part D specialty copay).

Medicaid:

• Coverage varies by state. Approximately 13 states cover Wegovy for weight loss as of 2026 (Medicaid and CHIP Payment and Access Commission 2026). Most states cover Ozempic for diabetes with prior authorization.
• Copay: $0 to $8 in most states.
• Savings card: Not available to Medicaid beneficiaries.
• Compounded semaglutide: Not covered.

Marketplace (ACA) plans:

• Coverage similar to employer plans but with higher cost-sharing. Silver plans typically place Ozempic and Wegovy on Tier 3 with 30% to 40% coinsurance after deductible.
• Effective cost: $200 to $400/month after deductible.
• Savings card reduces this to $50 to $250/month depending on coinsurance amount.

Veterans Affairs (VA):

• Ozempic and Wegovy available through VA formulary for eligible conditions.
• Copay: $0 to $11 depending on service-connected disability status and income.
• Savings card: Not available to VA beneficiaries.

TRICARE:

• Ozempic covered for diabetes. Wegovy not covered for weight loss.
• Copay: $13 to $38 depending on TRICARE plan type.
• Savings card: Not available to TRICARE beneficiaries (federal program exclusion).

FAQ

What is the cheapest way to get semaglutide? For patients earning under $60,240 annually (individuals) or $124,800 (family of 4), the Novo Nordisk Patient Assistance Program provides free brand-name Ozempic or Wegovy. For patients above that income threshold without insurance, compounded semaglutide at $179 to $299 monthly is cheapest.

How much does compounded semaglutide cost? Compounded semaglutide costs $179 to $299 per month depending on dose and platform. FormBlends charges $179 for starter doses and $229 to $279 for maintenance doses. Price includes medication, supplies, telehealth visit, and clinical support.

Is compounded semaglutide cheaper than Ozempic? Compounded semaglutide ($179 to $299/month) is cheaper than Ozempic cash price ($940 to $1,150/month) but more expensive than Ozempic with the Novo Nordisk savings card ($25 to $75/month for eligible patients with commercial insurance).

Can I use GoodRx to get cheap semaglutide? GoodRx coupons reduce brand-name Ozempic or Wegovy cash price by $50 to $150, bringing cost to $850 to $1,000 per month. This is still more expensive than compounded semaglutide. GoodRx doesn't apply to compounded medications.

Does insurance cover compounded semaglutide? Most insurance plans don't cover compounded semaglutide. Some plans with compounding pharmacy benefits allow reimbursement of 50% to 80% after you pay cash and submit a manual claim. Check your plan's compounding coverage before assuming no coverage.

What is the Novo Nordisk savings card? The Novo Nordisk savings card reduces brand-name Ozempic or Wegovy copays to as low as $25 per month for patients with commercial insurance. Maximum savings is approximately $150 per fill. Valid for 24 fills over 24 months. Not available to Medicare, Medicaid, or other government program beneficiaries.

How do I qualify for free semaglutide? Apply for the Novo Nordisk Patient Assistance Program if your income is below 400% of federal poverty level ($60,240 for individuals in 2026). Your provider submits the application with income documentation. Approval takes 5 to 10 days. Medication is shipped free for 12 months, renewable annually.

Is semaglutide from Mexico or Canada safe? Semaglutide from international pharmacies carries risk of counterfeit product, temperature degradation during shipping, and potential Customs seizure. The FDA documented counterfeit Ozempic in international supply chains in 2024. U.S. compounded semaglutide at $179 to $299/month is safer and often cheaper than international options.

Why is Ozempic so expensive without insurance? Brand-name Ozempic costs $940 to $1,150 monthly at cash price because Novo Nordisk sets the U.S. list price. The same medication costs $200 to $300 monthly in Canada and Europe due to government price negotiations. U.S. prices reflect the absence of federal price controls on prescription drugs.

Can I switch from brand-name Ozempic to compounded semaglutide? Yes. Compounded semaglutide contains the same active ingredient as Ozempic. Your provider can write a new prescription for compounded semaglutide and transfer your current dose. Most patients switch to reduce cost when insurance copays are high or coverage is denied.

Does FormBlends accept insurance for semaglutide? FormBlends compounded semaglutide is cash-pay only. We don't process insurance directly. Some patients submit receipts to their insurance for out-of-network reimbursement if their plan covers compounding. Monthly cost is $179 to $279 depending on dose.

What's the difference between cheap semaglutide and brand-name semaglutide? Compounded semaglutide is not FDA-approved, comes in a vial instead of a pre-filled pen, and requires drawing doses with a syringe. Brand-name Ozempic and Wegovy are FDA-approved with pen delivery. Both contain the same active ingredient (semaglutide) and work through the same mechanism.

How long does a vial of compounded semaglutide last? A 2.5 mg vial lasts 4 weeks at starter doses (0.25 mg to 0.5 mg weekly) or 2 weeks at higher doses (1 mg to 1.25 mg weekly). A 5 mg vial lasts 4 weeks at maintenance doses (1 mg to 2 mg weekly). FormBlends ships vials timed to your dose schedule.

Can I use an HSA or FSA to pay for compounded semaglutide? Yes. Compounded semaglutide is an eligible medical expense for Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). Save your receipts for reimbursement or use your HSA/FSA debit card at checkout if your platform accepts it.

Is there a generic semaglutide? No. Semaglutide is still under patent protection through 2031. Generic semaglutide won't be available until after patent expiration. Compounded semaglutide is not a generic. It's a compounded preparation made under a different regulatory pathway (503A/503B compounding).

Sources

1. Sharma R et al. Patient Assistance Program Utilization for GLP-1 Receptor Agonists in Federally Qualified Health Centers. J Community Health. 2025.
2. FDA Safety Alert. Counterfeit Semaglutide Products Identified in U.S. Supply Chain. December 2024.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
5. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
6. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
7. KFF Employer Health Benefits Survey. Coverage of Anti-Obesity Medications. 2025.
8. Medicaid and CHIP Payment and Access Commission (MACPAC). State Coverage of Anti-Obesity Medications. March 2026.
9. Novo Nordisk. Ozempic Prescribing Information. Revised January 2024.
10. Novo Nordisk. Wegovy Prescribing Information. Revised January 2024.
11. GoodRx Research. Prior Authorization Requirements for GLP-1 Medications. 2024.
12. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
13. U.S. Department of Health and Human Services. Federal Poverty Guidelines. 2026.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.